The use of drugs for the treatment of xerostomia – brief review

  • Abstract
  • Keywords
  • References
  • PDF
  • Abstract

    Inadequate production of saliva causes an oral imbalance that has a great impact on the individual's quality of life. Diseases of various types are responsible for impaired production of saliva and dry mouth, as happens in xerostomia. It is usually associated with hypofunction of the salivary glands, which shows signs of dryness on oral mucosa, and other morphological features in the oral cavity. Saliva is composed of water and 1% of electrolytes and immunoglobulins, enzymes and other proteins. Its fluid component, which contains ions, is mainly produced by parasympathetic stimulation, while the protein component, produced in the acinar secretory vesicles, is released by sympathetic stimulation. The use of certain drugs is a major cause of xerostomia. Among these we found analgesics, anticonvulsants, antihistamines, antihypertensives, diuretics and antidepressants. The treatment is mainly done by saliva substitutes such as sodium chloride, potassium chloride, monopotassium phosphate and dipotassium phosphate. However, in some cases, stimulants, such as citric acid and sodium citrate, or even topical salivary substitutes can be effective. Furthermore, the use of specific oral care products is well accepted by the patients. The treatment is selected according to the ability of the glands to produce saliva. It is still not fully known what mechanism of action drugs that cause hyposalivation, dry mouth or changes in saliva composition use. Yet, it is important to know the side effects of prescribed drugs.

  • Keywords

    : Drugs; Hyposalivation; Oral Care; Xerostomia.

  • References

      [1] M. Navazesh; C. Christensen; V. Brightman. Clinical criteria for the diagnosis of salivary gland hypofunction. J Dent Res 1992; 71:1363-9.

      [2] T.O. Narhi; J.H. Meurman; A. Ainamo. Xerostomia and hyposalivation: causes, consequences and treatment in the elderly. Drugs Aging 1999; 15: 103-16.

      [3] R.A.A.Fávaro; T.N.R. Ferreira; W.D. Martins. "XEROSTOMIA: etiologia, diagnóstico e tratamento. Revisão." Archives of Oral Research 2.4 (2006).

      [4] P.C. Fox; P.F. van der Ven; B.C. Sonies; J.M. Weiffenbach; B.J Baum. Xerostomia: evaluation of a symptom with increasing significance. J Am Dent Assoc 1985; 110: 519-25.

      [5] M. Edgerton; L.A. Tabak; M.J. Levine. Saliva: a significant factor in removable prosthodontic treatment. J Prosthet Dent 1987; 57:57-66.

      [6] I.D. Mandel. The role of saliva in maintaining oral homeostasis. J Am Dent Assoc 1989;119:298-304.

      [7] C.A. Murdoch-Kinch; N. Russo; S. Griffith; T. Braun; A. Eisbruch; N.J. D`Silva. Recovery of salivary epidermal growth factor in parotid saliva following parotid sparing radiation therapy: a proof-of-pinciple study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97(1):64-67.

      [8] M.A. Cabrera; A.E. Mesas; L.A. Rossato; S.M. Andrade. Fluxo salivar e o uso de drogas psicoativas em idosos. Rev Assoc Med Bras 2007; 53(2): 178-81.

      [9] P.F. Denise; M.H.M. Lícia; L.P. Aline; B.B. Ana Cristina. Sialometria; aspectos de interesse clínico. Ver Bras Reumatol. 2010; 53(6):525-531.

      [10] S.P. Humphrey; R.T. Williamson. A review of saliva: normal composition, flow, and function. J Prosthet Dent 2001; 85:162-9.

      [11] P.M. Smith. Mechanisms of salivary secretion. Saliva and oral health. London: British Dental Association, (2004) 14-31

      [12] W.M. Edgar; D.M. O’Mullane. Saliva and oral health. 2nd ed. London: British Dental Association; 1986. p. 39.

      [13] P.C. Fox. Saliva composition and its importance in dental health. Compend Suppl 1989; 13:S457-60.

      [14] J. Tenovuo. Antimicrobial function of human saliva—how important is it for oral health? Acta Odontol Scand 1998;56:250-6.

      [15] A.C.C. Vidal; G.A. Lima; S. Grinfeld. Pacientes Idosos: Relação entre xerostomia e o uso de diuréticos, antidepressivos e antihipertensivos/Old-age pacientes: Report between drynees mouth sensation and utilization of diuretics, antidepressives agents and antihypertensives agents. IJD. International Journal of Dentistry 3.1 (2008): 330-335.

      [16] B.J. Baum. Neurotransmitter control of secretion. J Dent Res 1987; 66:628-32.

      [17] M.G. Lee; E. Ohana; H.W. Park; D. Yang; S. Muallem. Molecular mechanism of pancreatic and salivary gland fluid and HCO3 secretion. Physiol Rev. 2012; 92:39–74. [PubMed: 22298651]

      [18] A. Nanci. Ten Cate Histologia Oral – desenvolvimento, estrutura e função. 8ª ed. Rio de Janeiro: Elsevier, 2013, 400p.

      [19] C.R. Douglas. Tratado de Fisiologia Aplicada às Ciências Médicas, 6ed, Guanabara Koogan, Rio de Janeiro, Brasil, 2006.

      [20] R.M. Berne. Physiology. 4th ed. St. Louis: Mosby; 1998.

      [21] G.W. Carlson. The salivary glands. Embryology, anatomy, and surgical applications. Surgical Clinics of North America 2000; 80:261-73.

      [22] C.C. Michel. Fluid movements through capillary walls. In: Handbook of Physiology. The Cardiovascular System. Microcirculation. Bethesda, MD: Am. Physiol. Soc., 1984, sect. 2, vol. IV, pt. 1, chapt. 9, p. 375–410.

      [23] J. Ekström; J.R. Garret; B. Mansson; G. Tobin; The effects of atropine and chronic sympathectomy on maximal parasympathetic stimulations of parotid saliva in rats; Journal of Physiology (1988), 403, pp 105-116

      [24] H.P. Rang; M.M. Dale; J.M. Ritter; R.J. Flower; G. Henderson. Farmacologia de Rang & Dale. 7ed, Elsevier, Rio de Janeiro, Brasil, 2012.

      [25] V.I. Horn; B.J. Baum; I.S. Ambudkar. Beta-adrenergic receptor stimulation induces inositol trisphosphate production and Ca2+ mobilization in rat parotid acinar cells. I Biol Chem (1988) 263:12454-12460.

      [26] V.I. Horn; B.J. Baum BJ; I.S. Ambudkar. Evidence for the convergence of beta-adrenergic and muscarinic signaling systems at a post-receptor site. FEBS Lett (1989) 258(1):13-16.

      [27] R.L. Wynn; T.F. Meiller. Drugs and dry mouth. Gen Dent 2001;49:10-4

      [28] C.B.E. Scully. Drug Effects on Salivary Glands: Dry Mouth. Oral Diseases2003; 9 (10):165-76.

      [29] W.S. Anthes;M.J. Blaser; B. Reiller; Acute suppurative parotitis associated with anaerobic bacteria. Am. J.Clin. Pathol.-75:160; 1981.

      [30] N.V.A. Amerogen, E.C.I. Veerman. Saliva - The defender of the oral cavity. Oral Dis 2002; 8(1):12-22.

      [31] A.S. Tucker; I. Miletich. Salivary glands: Developoment, Adaptations and Disease. Front Oral Biol, Karger Medical and Scientific Publishers, 2010, vol.14, pp 1-20.

      [32] M. Kwak; S. Ghazizadeh. Analysis of histone H2BGFP retention in mouse submandibular gland reveals actively dividing stem cell populations. Stem Cells Dev. 2015; 24(5):565–74.

      [33] J.G. Batsakis; E.G. Bernacki; D.H. Rice; M.E. Stebler. Malignancy and the benign epithelial lesion; Laringoscope; - 85:389; 1975.

      [34] F. Agha-Hosseini, I. Mirzaii-Dzgah, P.P. Moghaddam, Z.T. Akrad. Stimulated whole salivary flow rate and composition in menopausal women with oral dryness feeling. Oral Dis 2007; 13(3): 320-3.

      [35] A.R. Dehpour; M. Abdollahi; H. Alghasi. Effects of lithium on rat parotid and submandibulary gland functions. Gen Pharmacol. 1995 Jul;26(4):851-4.

      [36] J.V. Soames, J.C. Southam. Oral Pathology. 3 ed. Oxford: Oxford University Press. 1998:245-65.

      [37] D.H. Rice; D.W. Eisele. Salivary Gland Diseases. The Otolaryngologic Clinics of Northmerica 32:5 1999.

      [38] J.J. Mullins; L.J. Mullins; D.R. Dunbar; W.J. Brammar; K.W. Gross; S.D. Morley. Identification of a human ortholog of the mouse Dcpp gene locus, encoding a novel member of the CSP-1/Dcpp salivary protein family. Physiol Genomics. 2006; 28(1):129–40.

      [39] J.D. Giovanni. Drugs and the geriatric patient: a review of problems and special considerations faced by the dentist. Special Care in Dentistry 10.5 (1990): 161-163.

      [40] B.J. Bailey. Head and Neck Surgery-Otolaryngology. Philadelphia, JB Lippincott Company, 1998, vol. 1, caps. 39, 40 e 41.

      [41] E. Katchburian; V.E. Arana. Histologia e Embriologia Oral: texto, atlas e correlações clínicas. 1 ed. São Paulo. Panamericana. 1999:119-50.

      [42] M.J. Kortsanje. Drug induced mouth disorders. Clinical and experimental. Dermatology 1995; 20-8.

      [43] S.K. Lee; S.W. Lee; S.C. Chung; Y.K. Kim; H.S. Kho. Analysis of residual saliva and minor salivary gland secretions in patients with dry mouth. Arch Oral Biol 2002; 47(9):637-41.

      [44] O.H. Lowry; N.J. Rosebrough; A.L. Farr; R.J. Randall. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193(1):265-75.

      [45] W.J. Loesche; J. Bromberg; M.S. Terpenning; W.A. Bretz; B.L. Domingues; N.S. Grossman. Xerostomia, xerogenic medications and food avoidances in selected geriatric groups. J. Am Geriatric Soc 1995; 43(4):401-7.

      [46] C. Llena--Puy. The role of saliva in maintaning oral helath and as an aid to diagnosis. Med Oral Patol Oral Cir Bucal, 2006; 11(5):E449-55.

      [47] L.M. Sreebny; S.S. Schwartz. A reference guide to drugs and dry mouth — 2nd edition. Gerodontology 1997. 14, 33–47.

      [48] Y. S. Dai, I. S. Ambudkar, V. J. Horn, C. K. Yeh, E. E. Kousvelari, S. J. Wall, M. Li, R. P. Yasuda, B. B. Wolfe, B. J. Baum. Evidence that M3 muscarinic receptors in rat parotid gland couple to two second messenger systems. American Journal of Physiology-Cell Physiology 261.6 (1991): C1063-C1073.

      [49] E. L. Watson, P. W. Abel, D. DiJulio, W. Zeng, M. Makoid, K. L. Jacobson, L. T. Potter, F. J. Dowd. Identification of muscarinic receptor subtypes in mouse parotid gland. Am J Physiol 1996, 271:C905-C913.

      [50] J.L. Pretorius; M. Phillips; R.W. Langley; E. Szabadi; C.M. Bradshaw. Comparison of clozapine and haloperidol on some autonomic and psychomotor function, and on serum prolactin concentration, in healthy subjects; (2001) Blackwell Science Ltd Br; J Clin Pharmacol, 52, 322-326.

      [51] S.R. Porter; C. Scully; M. Hegarty. An update of the etiology and management of xerostomia. O Surg O Med O Pathol Oral Radiol Endod. 2004; 97:28-46.

      [52] T. Nederfors. Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists. Swed Dent J. 1996; 116(Suppl):1-70.

      [53] S.R. Porter; C. Scully. Adverse drugs reactions in the mouth. Clin Dermatol. 2000; 18:525-32.

      [54] G.H. Gilbert; M.W. Heft; R.P. Duncan. Mouth dryness as report by older florians community. Dent /oral. Epidemiol 1993; 21(6):390-7.

      [55] J.R. Martinez. Treatment of salivary gland disorders: alternative approaches. National Institute of Dental & Craniofacial Research (NIDCR); Building 31, Conference Room 10; National Institutes of Health Bethesda, Maryland 20892; July 30-31, 2001, Available from URL:

      [56] J.H. Meurman; P. Ranto; H. Pajukoski; R. Sulkava. Salivary albumin and other constituents and their relation to oral and general health in the elderly. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94(4):432-8.

      [57] L.M.H.D. Mota, B.A. Cruz, C.V. Brenol et al. Consenso da Sociedade Brasileira de Reumatologia 2001 para o diagnóstico e avaliação inicial da artrite reumatóide. Bras J Rheumatol 2011;51(3):207-19.

      [58] M.S.M. Soares; J.M.C. Lima; S.C.C. Pereira; Avaliação do fluxo salivar, xerostomia e condição psicológica em mulheres com síndrome da ardência bucal. Rev Odontol UNESP. 2008;37(4):315-319.

      [59] H. Mortazavi; M. Baharvand; A. Movahhedian; M. Mohammadi; A. Khodadoustan. Xerostomia due to systemic disease: a review of 20 conditions and mechanims. Ann Med Helath Sci Res. 2014 jul; 4(4):503-10.

      [60] A. Davies. The management of xerostomia: a review. European Journal of Cancer Care 1997; 6:209-14.

      [61] M.P López Jornet, G. García Teresa, M. Viñas, T. Vinuesa. Clinical and antimicrobial evaluation of a mouthwash and toothpaste for xerostomia: a randomized, double-blind, crossover study. J Dent. 2011 Nov;39(11):757-63

      [62] W. Niedermeir; C. Matthaeus; C. Meyer; S. Staar; R.P. Muller; H.J. Schulze. Radiation-induced hyposalivation and its treatment with oral pilocarpine. Oral Medicine Oral Pathology Oral Radiology & Endodontics 1998; 86(5):541-9.

      [63] S.L. Russel; S. Reisine. Investigation of Xerostomia in Patients with Rheumatoid Arthritis. Journal of the American Dental Association 1998; 129:733-739.

      [64] E.A. Field; L.P. Longman; R. Bucknall; S.B. Kaie; S.M. Higham; W.M. Edgar. The establishment of a xerostomia clinics: a prospective study.Brazilian Journal of Oral Maxillofacial Surgery 1997; 35 (2):96-103.

      [65] S. Holmes. The Management of Xerostomia in Older Adults. Reviews in clinical gerontology 1999; 9:317-26.

      [66] C.H.S. Pedrazas; L.N.M. Azevedo; T.R. Torres. Manejo do paciente com hipossalivação; Revista PerioNews 2007, 1(4):369-73.

      [67] A.N. Amerongen and E. Veerman. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Supportive care in cancer 11.4 (2003): 226-231.

      [68] A. Ithagarun; S.H. Wel. Chewing gum and saliva in oral health. J Clin Dent. 1997; 8:159-60.

      [69] P. Warde; B. Kroll; B. O'Sullivan; J. Aslanidis; E. Tew-George; J. Waldron; W. Maxymiw; F.-F. Liu; D. Payne; B. Cummings. A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer. 2000; 8:203-08.

      [70] A.N. Davies. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. Palliat Med. 2000; 14:197-203.

      [71] D.S.F. Boarim. Nutricao, Saude & Naturismo. Sao Paulo: Edicoes Vida Plena; 1991.

      [72] M.M. Grisius. Salivary gland dysfunction: A review of systemic therapies. Oral Surgery Oral Medicine Oral Pathology Oral Radiology & Endodontics 2001; 92(2):156-62.

      [73] S.R. Torres; C.B. Peixoto; D.M. Caldas; T. Akiti; M.G.C. Barreiros; M. Uzeda; M. Nucci. A prospective randomized trial to reduce oral Candida spp.colonization in patients with hyposalivation. Brazilian Oral Research 2007; 21:182-7.

      [74] O. Tarzia. Halitose – Um desafio que tem cura. 2a ed. Rio de Janeiro: EPUB; 2004.

      [75] R.P. Zimmerman; R.J. Mark; L.M. Tran; G.F. Juillard. Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia. Int J Radiat Oncol Biol Phys 1997; 37:571-5.

      [76] P. Haddad; M. Karimi. A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiationinduced xerostomia. Radiother Oncol 2002; 64:29-32.

      [77] A.S. Papas; M.M. Fernandez; R.A. Castano; S.C. Gallagher; M. Trivedi; R.C. Shrotriya. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with primary Sjogren’s syndrome. Advances in experimental Medicine and Bilology 1998; 438:973-8.

      [78] C.P. Bots; H.S. Brand; E.C.I. Veerman; J.C. Korevaar; M. Valentijn-Benz; P.D. Bezemer; R.M. Valentijin; P.F. Vos; J.A. Bijlsma; P.M. ter Wee; B.M. Van Amerongen; A.V.N. Amerongen. Chewing gum and saliva substitute alleviate thirst and xerostomia in pacients on haemodialysis. Nephrology dialysis transplantation. Nephrology dialysis transplantation 20.3 (2005): 578-584.

      [79] ANVISA. Agência Nacional de Vigilância Sanitária.

      [80] Y. Iwabuchi; T. Masuhara. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjorgen’s syndrome. Gen Pharmacol 1994 Jan; 25 (1): 123-9

      [81] J. Rosas; M. Ramos‐Casals; J. Ena; M. García‐Carrasco; J. Verdu; R. Cervera; J. Font; O. Caballero; M. Ingelmo; E. Pascual. Usefulness of Basal and Pilocarpine-Stimulate salivary flow in primary Sjogren’s syndrome. Correlation with clinical, immunological and histological features. Rheumatology 2002; 41:670-5.

      [82] A.S. Papas; Y.S. Sherrer; M. Charney; H.E. Golden; T.A.J. Medsger; B.T. Walsh; M. Trivedi; B. Goldlust; S. Gallagher. Successful treatment of dry mouth and dry eye symptoms in Sjogren’s Syndrome patients with oral pilocarpine: A randomized, placebo-controlled, dose-adjustment study. Journal of Clinical Rheumatology 2004;10(4):169-77.

      [83] J. Weber; G.M. Keating. Cevimeline. Drugs. 68, 12, 1691-1698, July 15, 2008.

      [84] J.B. Epstein; J.L. Burchell; S. Emerton; N.D. Le; S. J. Silverman; A clinical trial of bethanechol in patients with xerostomia after radiations therapy. A pilot study. Oral Surg Oral Med Oral Pathol 1994; 77:610-4

      [85] N. Salazar-Sanches; P. Lopez-Jornet; F. Camacho-Alonso; M. Sanchez-Siles. Efficacy of topical Aloe vera in patients with oral lichen planus: a randomized double-blind study. Journal of Oral Pathology and Medicine, v.39, n.10, p.735-40, 2010.

      [86] Y. Ukai; N. Taniguchi; K. Takeshita; K. Kimura; H. Enomoto. Chronic anethole trithione treatment enhances the salivary secretion and increases the muscarinic acetylcholine receptors in the rat submaxillary gland. Arch Int Pharmacodyn Ther 1984; 271:206-12

      [87] Y. Ukai; N. Taniguchi; K. Takeshita; T. Ogasawara; K. Kimura. Enhancement of salivary secretion by chronic anethole trithione treatment. Arch Int Pharmacodyn Ther 1988; 294:248-58.

      [88] Y. Ukai; N. Taniguchi; A. Yamazaki; K. Kimura. Enhancement of phosphatidylinositol turnover and cyclic nucleotide accumulation by chronic anethole trithione treatment in rat submaxillary glands. J Pharm Pharmacol 1989;41:247-52.

      [89] T. Hamada; T. Nakani; T. Kimura; K. Arisawa; K. Yoneda; T. Yamamoto; T. Osaki. Treatment of xerostomia with the bile secretion-stimulating drug anethole trithione: A Clinical trial. The American Journal of Medical Sciences 1999; 318 (3):146.

      [90] J.S. Jiménez; C.A.R. Herrera; F.A. Blanco; R.E.A. Arévalo; M.M. Martínez. Manejo Terapéutico de la xerostomía en Atención Primaria. Medicina de familia, 2004, 1, 42-9.

      [91] J.B. Epstein; M.M Schubert. Synergistic effect of sialagogues in management of xerostomia after radiation therapy. Oral Surg Oral Med Oral Pathol 1987; 64:179-82.

      [92] J.B. Epstein; W.E. Decoteau; A. Wilkinson. Effect of Sialor in tratment of xerostomia in Sjögren’s syndrome. Oral Surg 1983; 56:495-9.

      [93] C.L. Jones; C.A. Saxton; J.A. Ritchie. Microbiological and clinical effects of a dentifrice containing zinc citrate and triclosan in the human experimental gingivitis model. Journal of Clinical Periodontology 1990; 17:570–4.

      [94] C. Spry; K. Kirk; K.J. Saliba. Coenzyme A biosynthesis: an antimicrobial drug target FEMS Microbiology Reviews Jan 2008, 32 (1) 56-06;

      [95] S. Boisnic, L.B. Slama; M.C. Branchet-Gumila; M. Watts; G. d'Arros. Efecto antiinflamatorio de la enoxolona en un modelo exvivo de mucosa gingival humana. Rev. Fundac. Juan Jose Carraro, 16(33), 2011, 18-23.

      [96] R. Arancibia; M. Caceres; J. Martinez. Triclosan inhibits tumor necrosis factor-alpha-stimulated urokinase production in human gingival fibroblast. Journal of Periodontal Research, v.44, n.6, p.726-735, 2009.

      [97] M. Dunér-Engström; B.B. Fredholm; O. Larsson; J.M. Lundberg; A. Saria. Autonomic mechanisms underlying capsaicin induced oral sensations and salivation in man. The Journal of physiology, 1986, 373, 87.

      [98] P. GJÖRSTRUP. "Taste and chewing as stimuli for the secretion of amylase from the parotid gland of the rabbit." Acta Physiologica Scandinavica 110.3 (1980): 295-301.

      [99] F. Femiano; R. Rullo; A. Lanza; V.M. Festa; N. Crillo. A comparison of salivar substitutes versus a natural sialogogue (citric acid) in patients complaining of dry mouth as an adverse drug reaction: a clinical, randomized controlled study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011, 112(1), pp. e15-e20.

      [100] D.J. Aframian; M. Helcer; D. Livni; S.D. Robinson; A. Markitziu; C. Nadler. Pilocarpine treatment in a mixed cohort of xerostomic patients. Oral Dis 2007;13:88-92.

      [101] A. Wolff; L. Zuk-Paz; I. Kaplan. Major salivary gland output differs between users and nonusers of specific medication categories. Gerodontology 2008;25:210-6.

      [102] A. Gaffar; N. Nabi; B. Kashuba; M. Williams; S. Herles; S. Olsen; J. Afflitto. Antiplaque effects of dentifrices containing triclosan/copolymer/NaF system versus triclosan dentifrices without the copolymer. American journal of dentistry, 1990, 3, S7-14.

      [103] R.D. Jones; H.B. Jampani; J.L. Newman; A.S. Lee. Triclosan: a review of effectiveness and safety in health care settings. American journal of infection control, (2000), 28(2), 184-196.

      [104] K.T. Villalpando; R.C.V. Casarin; S.P. Pimentel; F.R. Cirano; M.Z. Casati. A randomized clinical evaluation of triclosancontaining dentifrice and mouthwash association in the control of plaque and gingivitis. Quintessence International, 2010, 41(10).

      [105] J.A. Ship. Diagnosing, managing, and preventing salivary gland disorders. Oral diseases 2002; 8(4):77-89.

      [106] J.A. Ship. Xerostomia and the geriatric patient. Journal of the American Geriatrics Society 2002; 50(3):535-43.

      [107] J.A. Cury; C. Feller. "Flúor: dos 8 aos 80?."Atualização na clínica odontológica: o dia a dia do clínico geral. Artes Médicas, 1992. 375-82.

      [108] K.G. König; Diet and oral health. International Dental Journal 50.3 (2000): 162-174.

      [109] J.D.B. Featherstone. Prevention and reversal of dental caries: role of low level fluoride. Community dentistry and oral epidemiology 27.1 (1999): 31-40.

      [110] M.A. Gales; T.M. Nguyen. Sorbitol compared with xylitol in prevention of dental caries. Annals of Pharmacotherapy 34.1 (2000): 98-100.

      [111] G. W. Burton; M. G. Traber. Vitamin E: antioxidant activity, biokinetics, and bioavailability. Annual Review of Nutrition, vol. 10, 1990, pp. 357–382

      [112] M. Konopacka; M. Widel; J. Rzeszowska-Wolny. Modifying effect of vitamins C, E and beta-carotene against gamma-ray-induced DNA damage in mouse cells. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 417.2 (1998): 85-94.

      [113] A. Azzi, R. Ricciarelli, and J.-M. Zingg, “Non-antioxidant molecular functions of α-tocopherol (vitamin E),” FEBS Letters, vol. 519, no. 1–3, pp. 8–10, 2002.

      [114] F. Zonta; P. Bogoni; P. Masotti; G. Micali. High-performance liquid chromatographic profiles of aloe constituents and determination of aloin in beverages, with reference to the EEC regulation for flavouring substances. Journal of Chromatography A, (1995) 718(1), 99-106.

      [115] D.E. Pratt; B.J.F. Hudson. Natural antioxidants not exploited commercially. Food antioxidants. Springer Netherlands, 1990. 171-191.

      [116] R.H. Davis; K.Y. Rosenthal; L.R. Cesario; G.A. Rouw. Processed Aloe vera administered topically inhibits inflammation. Journal of the American Podiatric Medical Association, (1989) 79(8), 395-397.

      [117] J.A. Hutter; M. Salman; W.B. Stavinoha; N. Satsangi; R.F. Williams; R.T. Streeper; S.T. Weintraub. Antiinflammatory C-glucosyl chromone from Aloe barbadensis. Journal of natural products, 1996, 59(5), 541-543.

      [118] P. Haddad; F. Amouzgar-Hashemi; S. Samsami; S. Chinichian; M.A. Oghabian. Aloe vera for prevention of radiation-induced dematitis: a self-controlled clinical trial. Curr Oncol; 20 (4): 345-8, 2013 Aug

      [119] G.A. Royack, M.P. Nguyen, D.C. Tong, M. Poot, D. Oda; Response of human oral epithelial cells to oxidative damage and the effect of vitamin E; Oral Oncology 36 (2000).

      [120] S.R. Torres; R.S. Lotti; C.B. Peixoto; P.A.C. Graça; M.E.P. Lima; C.C. Pina M. Nucci; M. Uzeda. Eficácia de um questionário para detecção de hipossalivação. Revista Associacao Paulista de Cirurgiões-Dentistas 2002; 56:227-31.




Article ID: 6708
DOI: 10.14419/ijbas.v5i4.6708

Copyright © 2012-2015 Science Publishing Corporation Inc. All rights reserved.